Solventum Corporation (NYSE: SOLV) Stock Competitors & Peer Comparison
See SOLV's competitors and their performance on the NYSE and across the wider stock market.
Peer Comparison Table: Medical - Care Facilities Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for SOLV and its NYSE peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| SOLV | $78.01 | +1.00% | 13.5B | 12.50 | $6.24 | N/A |
| HCA | $382.19 | +1.51% | 84.8B | 13.20 | $28.96 | +0.78% |
| THC | $233.20 | +17.17% | 20.1B | 13.53 | $17.24 | N/A |
| DVA | $235.44 | +0.50% | 15.1B | 20.06 | $11.73 | N/A |
| FMS | $24.59 | +0.61% | 13.2B | 9.76 | $2.52 | +3.52% |
| EHC | $112.89 | +1.65% | 11.2B | 19.83 | $5.69 | +0.67% |
| ENSG | $172.99 | +3.27% | 10.1B | 25.07 | $6.90 | +0.15% |
| UHS | $155.75 | +2.96% | 9.8B | 6.91 | $22.54 | +0.51% |
| OSH | $39.00 | +0.08% | 9.5B | -17.65 | -$2.21 | N/A |
| PACS | $46.85 | +4.53% | 7.4B | 39.80 | $1.18 | N/A |
Stock Comparison
HCA Healthcare, Inc. (NYSE: HCA)
SOLV vs HCA Comparison July 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.5B. In comparison, HCA has a market cap of 84.8B. Regarding current trading prices, SOLV is priced at $78.01 on the NYSE, while HCA trades at $382.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.50, whereas HCA's P/E ratio is 13.20. In terms of profitability, SOLV's ROE is +0.31%, compared to HCA's ROE of -1.54%. Regarding short-term risk, SOLV is less volatile compared to HCA. This indicates lower risk in terms of short-term price fluctuations for SOLV.Check HCA's competition here
Tenet Healthcare Corporation (NYSE: THC)
SOLV vs THC Comparison July 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.5B. In comparison, THC has a market cap of 20.1B. Regarding current trading prices, SOLV is priced at $78.01 on the NYSE, while THC trades at $233.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.50, whereas THC's P/E ratio is 13.53. In terms of profitability, SOLV's ROE is +0.31%, compared to THC's ROE of +0.38%. Regarding short-term risk, SOLV is less volatile compared to THC. This indicates lower risk in terms of short-term price fluctuations for SOLV.Check THC's competition here
DaVita Inc. (NYSE: DVA)
SOLV vs DVA Comparison July 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.5B. In comparison, DVA has a market cap of 15.1B. Regarding current trading prices, SOLV is priced at $78.01 on the NYSE, while DVA trades at $235.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.50, whereas DVA's P/E ratio is 20.06. In terms of profitability, SOLV's ROE is +0.31%, compared to DVA's ROE of -1.33%. Regarding short-term risk, SOLV is less volatile compared to DVA. This indicates lower risk in terms of short-term price fluctuations for SOLV.Check DVA's competition here
Fresenius Medical Care AG & Co. KGaA (NYSE: FMS)
SOLV vs FMS Comparison July 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.5B. In comparison, FMS has a market cap of 13.2B. Regarding current trading prices, SOLV is priced at $78.01 on the NYSE, while FMS trades at $24.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.50, whereas FMS's P/E ratio is 9.76. In terms of profitability, SOLV's ROE is +0.31%, compared to FMS's ROE of +0.07%. Regarding short-term risk, SOLV is more volatile compared to FMS. This indicates higher risk in terms of short-term price fluctuations for SOLV.Check FMS's competition here
Encompass Health Corporation (NYSE: EHC)
SOLV vs EHC Comparison July 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.5B. In comparison, EHC has a market cap of 11.2B. Regarding current trading prices, SOLV is priced at $78.01 on the NYSE, while EHC trades at $112.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.50, whereas EHC's P/E ratio is 19.83. In terms of profitability, SOLV's ROE is +0.31%, compared to EHC's ROE of +0.25%. Regarding short-term risk, SOLV is less volatile compared to EHC. This indicates lower risk in terms of short-term price fluctuations for SOLV.Check EHC's competition here
The Ensign Group, Inc. (NASDAQ: ENSG)
SOLV vs ENSG Comparison July 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.5B. In comparison, ENSG has a market cap of 10.1B. Regarding current trading prices, SOLV is priced at $78.01 on the NYSE, while ENSG trades at $172.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.50, whereas ENSG's P/E ratio is 25.07. In terms of profitability, SOLV's ROE is +0.31%, compared to ENSG's ROE of +0.17%. Regarding short-term risk, SOLV is less volatile compared to ENSG. This indicates lower risk in terms of short-term price fluctuations for SOLV.Check ENSG's competition here
Universal Health Services, Inc. (NYSE: UHS)
SOLV vs UHS Comparison July 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.5B. In comparison, UHS has a market cap of 9.8B. Regarding current trading prices, SOLV is priced at $78.01 on the NYSE, while UHS trades at $155.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.50, whereas UHS's P/E ratio is 6.91. In terms of profitability, SOLV's ROE is +0.31%, compared to UHS's ROE of +0.21%. Regarding short-term risk, SOLV is less volatile compared to UHS. This indicates lower risk in terms of short-term price fluctuations for SOLV.Check UHS's competition here
Oak Street Health, Inc. (NYSE: OSH)
SOLV vs OSH Comparison July 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.5B. In comparison, OSH has a market cap of 9.5B. Regarding current trading prices, SOLV is priced at $78.01 on the NYSE, while OSH trades at $39.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.50, whereas OSH's P/E ratio is -17.65. In terms of profitability, SOLV's ROE is +0.31%, compared to OSH's ROE of +4.64%. Regarding short-term risk, SOLV is more volatile compared to OSH. This indicates higher risk in terms of short-term price fluctuations for SOLV.Check OSH's competition here
PACS Group, Inc. (NYSE: PACS)
SOLV vs PACS Comparison July 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.5B. In comparison, PACS has a market cap of 7.4B. Regarding current trading prices, SOLV is priced at $78.01 on the NYSE, while PACS trades at $46.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.50, whereas PACS's P/E ratio is 39.80. In terms of profitability, SOLV's ROE is +0.31%, compared to PACS's ROE of +0.27%. Regarding short-term risk, SOLV is less volatile compared to PACS. This indicates lower risk in terms of short-term price fluctuations for SOLV.Check PACS's competition here
Chemed Corporation (NYSE: CHE)
SOLV vs CHE Comparison July 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.5B. In comparison, CHE has a market cap of 6.8B. Regarding current trading prices, SOLV is priced at $78.01 on the NYSE, while CHE trades at $511.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.50, whereas CHE's P/E ratio is 23.66. In terms of profitability, SOLV's ROE is +0.31%, compared to CHE's ROE of +0.25%. Regarding short-term risk, SOLV is less volatile compared to CHE. This indicates lower risk in terms of short-term price fluctuations for SOLV.Check CHE's competition here
LHC Group, Inc. (NASDAQ: LHCG)
SOLV vs LHCG Comparison July 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.5B. In comparison, LHCG has a market cap of 5.3B. Regarding current trading prices, SOLV is priced at $78.01 on the NYSE, while LHCG trades at $169.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.50, whereas LHCG's P/E ratio is 82.83. In terms of profitability, SOLV's ROE is +0.31%, compared to LHCG's ROE of +0.04%. Regarding short-term risk, SOLV is more volatile compared to LHCG. This indicates higher risk in terms of short-term price fluctuations for SOLV.Check LHCG's competition here
LifeStance Health Group, Inc. (NASDAQ: LFST)
SOLV vs LFST Comparison July 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.5B. In comparison, LFST has a market cap of 4.2B. Regarding current trading prices, SOLV is priced at $78.01 on the NYSE, while LFST trades at $10.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.50, whereas LFST's P/E ratio is 173.65. In terms of profitability, SOLV's ROE is +0.31%, compared to LFST's ROE of +0.02%. Regarding short-term risk, SOLV is less volatile compared to LFST. This indicates lower risk in terms of short-term price fluctuations for SOLV.Check LFST's competition here
Concentra Group Holdings Parent, Inc. (NYSE: CON)
SOLV vs CON Comparison July 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.5B. In comparison, CON has a market cap of 4B. Regarding current trading prices, SOLV is priced at $78.01 on the NYSE, while CON trades at $31.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.50, whereas CON's P/E ratio is 21.95. In terms of profitability, SOLV's ROE is +0.31%, compared to CON's ROE of +0.46%. Regarding short-term risk, SOLV is less volatile compared to CON. This indicates lower risk in terms of short-term price fluctuations for SOLV.Check CON's competition here
Brookdale Senior Living Inc. (NYSE: BKD)
SOLV vs BKD Comparison July 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.5B. In comparison, BKD has a market cap of 3.6B. Regarding current trading prices, SOLV is priced at $78.01 on the NYSE, while BKD trades at $15.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.50, whereas BKD's P/E ratio is -26.11. In terms of profitability, SOLV's ROE is +0.31%, compared to BKD's ROE of +401.19%. Regarding short-term risk, SOLV is less volatile compared to BKD. This indicates lower risk in terms of short-term price fluctuations for SOLV.Check BKD's competition here
National HealthCare Corporation (AMEX: NHC)
SOLV vs NHC Comparison July 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.5B. In comparison, NHC has a market cap of 3.5B. Regarding current trading prices, SOLV is priced at $78.01 on the NYSE, while NHC trades at $225.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.50, whereas NHC's P/E ratio is 32.32. In terms of profitability, SOLV's ROE is +0.31%, compared to NHC's ROE of +0.12%. Regarding short-term risk, SOLV is less volatile compared to NHC. This indicates lower risk in terms of short-term price fluctuations for SOLV.Check NHC's competition here
Option Care Health, Inc. (NASDAQ: OPCH)
SOLV vs OPCH Comparison July 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.5B. In comparison, OPCH has a market cap of 3.4B. Regarding current trading prices, SOLV is priced at $78.01 on the NYSE, while OPCH trades at $21.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.50, whereas OPCH's P/E ratio is 12.59. In terms of profitability, SOLV's ROE is +0.31%, compared to OPCH's ROE of +0.15%. Regarding short-term risk, SOLV is less volatile compared to OPCH. This indicates lower risk in terms of short-term price fluctuations for SOLV.Check OPCH's competition here
Amedisys, Inc. (NASDAQ: AMED)
SOLV vs AMED Comparison July 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.5B. In comparison, AMED has a market cap of 3.3B. Regarding current trading prices, SOLV is priced at $78.01 on the NYSE, while AMED trades at $100.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.50, whereas AMED's P/E ratio is 39.30. In terms of profitability, SOLV's ROE is +0.31%, compared to AMED's ROE of +0.11%. Regarding short-term risk, SOLV is more volatile compared to AMED. This indicates higher risk in terms of short-term price fluctuations for SOLV.Check AMED's competition here
Acadia Healthcare Company, Inc. (NASDAQ: ACHC)
SOLV vs ACHC Comparison July 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.5B. In comparison, ACHC has a market cap of 3.2B. Regarding current trading prices, SOLV is priced at $78.01 on the NYSE, while ACHC trades at $34.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.50, whereas ACHC's P/E ratio is 17.34. In terms of profitability, SOLV's ROE is +0.31%, compared to ACHC's ROE of -0.44%. Regarding short-term risk, SOLV is less volatile compared to ACHC. This indicates lower risk in terms of short-term price fluctuations for SOLV.Check ACHC's competition here
Pediatrix Medical Group, Inc. (NYSE: MD)
SOLV vs MD Comparison July 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.5B. In comparison, MD has a market cap of 2.2B. Regarding current trading prices, SOLV is priced at $78.01 on the NYSE, while MD trades at $26.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.50, whereas MD's P/E ratio is 12.27. In terms of profitability, SOLV's ROE is +0.31%, compared to MD's ROE of +0.20%. Regarding short-term risk, SOLV is less volatile compared to MD. This indicates lower risk in terms of short-term price fluctuations for SOLV.Check MD's competition here
Addus HomeCare Corporation (NASDAQ: ADUS)
SOLV vs ADUS Comparison July 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.5B. In comparison, ADUS has a market cap of 2.1B. Regarding current trading prices, SOLV is priced at $78.01 on the NYSE, while ADUS trades at $114.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.50, whereas ADUS's P/E ratio is 17.79. In terms of profitability, SOLV's ROE is +0.31%, compared to ADUS's ROE of +0.09%. Regarding short-term risk, SOLV is less volatile compared to ADUS. This indicates lower risk in terms of short-term price fluctuations for SOLV.Check ADUS's competition here
Aveanna Healthcare Holdings Inc. (NASDAQ: AVAH)
SOLV vs AVAH Comparison July 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.5B. In comparison, AVAH has a market cap of 2.1B. Regarding current trading prices, SOLV is priced at $78.01 on the NYSE, while AVAH trades at $9.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.50, whereas AVAH's P/E ratio is 13.90. In terms of profitability, SOLV's ROE is +0.31%, compared to AVAH's ROE of +2.41%. Regarding short-term risk, SOLV is less volatile compared to AVAH. This indicates lower risk in terms of short-term price fluctuations for SOLV.Check AVAH's competition here
Surgery Partners, Inc. (NASDAQ: SGRY)
SOLV vs SGRY Comparison July 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.5B. In comparison, SGRY has a market cap of 2.1B. Regarding current trading prices, SOLV is priced at $78.01 on the NYSE, while SGRY trades at $15.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.50, whereas SGRY's P/E ratio is 40.33. In terms of profitability, SOLV's ROE is +0.31%, compared to SGRY's ROE of -0.04%. Regarding short-term risk, SOLV is less volatile compared to SGRY. This indicates lower risk in terms of short-term price fluctuations for SOLV.Check SGRY's competition here
Select Medical Holdings Corporation (NYSE: SEM)
SOLV vs SEM Comparison July 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.5B. In comparison, SEM has a market cap of 2B. Regarding current trading prices, SOLV is priced at $78.01 on the NYSE, while SEM trades at $16.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.50, whereas SEM's P/E ratio is 15.43. In terms of profitability, SOLV's ROE is +0.31%, compared to SEM's ROE of +0.08%. Regarding short-term risk, SOLV is more volatile compared to SEM. This indicates higher risk in terms of short-term price fluctuations for SOLV.Check SEM's competition here
Astrana Health, Inc. (NASDAQ: ASTH)
SOLV vs ASTH Comparison July 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.5B. In comparison, ASTH has a market cap of 2B. Regarding current trading prices, SOLV is priced at $78.01 on the NYSE, while ASTH trades at $40.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.50, whereas ASTH's P/E ratio is 27.24. In terms of profitability, SOLV's ROE is +0.31%, compared to ASTH's ROE of +0.04%. Regarding short-term risk, SOLV is less volatile compared to ASTH. This indicates lower risk in terms of short-term price fluctuations for SOLV.Check ASTH's competition here
Apollo Medical Holdings, Inc. (NASDAQ: AMEH)
SOLV vs AMEH Comparison July 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.5B. In comparison, AMEH has a market cap of 1.8B. Regarding current trading prices, SOLV is priced at $78.01 on the NYSE, while AMEH trades at $40.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.50, whereas AMEH's P/E ratio is 39.25. In terms of profitability, SOLV's ROE is +0.31%, compared to AMEH's ROE of +0.04%. Regarding short-term risk, SOLV is less volatile compared to AMEH. This indicates lower risk in terms of short-term price fluctuations for SOLV.Check AMEH's competition here
Agilon Health, Inc. (NYSE: AGL)
SOLV vs AGL Comparison July 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.5B. In comparison, AGL has a market cap of 1.6B. Regarding current trading prices, SOLV is priced at $78.01 on the NYSE, while AGL trades at $98.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.50, whereas AGL's P/E ratio is -9.57. In terms of profitability, SOLV's ROE is +0.31%, compared to AGL's ROE of -1.46%. Regarding short-term risk, SOLV is less volatile compared to AGL. This indicates lower risk in terms of short-term price fluctuations for SOLV.Check AGL's competition here
Innovage Holding Corp. (NASDAQ: INNV)
SOLV vs INNV Comparison July 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.5B. In comparison, INNV has a market cap of 1.6B. Regarding current trading prices, SOLV is priced at $78.01 on the NYSE, while INNV trades at $11.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.50, whereas INNV's P/E ratio is -128.44. In terms of profitability, SOLV's ROE is +0.31%, compared to INNV's ROE of -0.09%. Regarding short-term risk, SOLV is less volatile compared to INNV. This indicates lower risk in terms of short-term price fluctuations for SOLV.Check INNV's competition here
Healthcare Services Group, Inc. (NASDAQ: HCSG)
SOLV vs HCSG Comparison July 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.5B. In comparison, HCSG has a market cap of 1.6B. Regarding current trading prices, SOLV is priced at $78.01 on the NYSE, while HCSG trades at $22.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.50, whereas HCSG's P/E ratio is 18.19. In terms of profitability, SOLV's ROE is +0.31%, compared to HCSG's ROE of +0.23%. Regarding short-term risk, SOLV is less volatile compared to HCSG. This indicates lower risk in terms of short-term price fluctuations for SOLV.Check HCSG's competition here
Ardent Health Inc. (NYSE: ARDT)
SOLV vs ARDT Comparison July 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.5B. In comparison, ARDT has a market cap of 1.5B. Regarding current trading prices, SOLV is priced at $78.01 on the NYSE, while ARDT trades at $10.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.50, whereas ARDT's P/E ratio is 6.47. In terms of profitability, SOLV's ROE is +0.31%, compared to ARDT's ROE of +0.09%. Regarding short-term risk, SOLV is less volatile compared to ARDT. This indicates lower risk in terms of short-term price fluctuations for SOLV.Check ARDT's competition here
The Pennant Group, Inc. (NASDAQ: PNTG)
SOLV vs PNTG Comparison July 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.5B. In comparison, PNTG has a market cap of 1.4B. Regarding current trading prices, SOLV is priced at $78.01 on the NYSE, while PNTG trades at $41.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.50, whereas PNTG's P/E ratio is 33.46. In terms of profitability, SOLV's ROE is +0.31%, compared to PNTG's ROE of +0.09%. Regarding short-term risk, SOLV is less volatile compared to PNTG. This indicates lower risk in terms of short-term price fluctuations for SOLV.Check PNTG's competition here
AMN Healthcare Services, Inc. (NYSE: AMN)
SOLV vs AMN Comparison July 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.5B. In comparison, AMN has a market cap of 1.3B. Regarding current trading prices, SOLV is priced at $78.01 on the NYSE, while AMN trades at $32.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.50, whereas AMN's P/E ratio is 10.93. In terms of profitability, SOLV's ROE is +0.31%, compared to AMN's ROE of -0.05%. Regarding short-term risk, SOLV is less volatile compared to AMN. This indicates lower risk in terms of short-term price fluctuations for SOLV.Check AMN's competition here
Brookdale Senior Living Inc. 7. (NYSE: BKDT)
SOLV vs BKDT Comparison July 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.5B. In comparison, BKDT has a market cap of 1.2B. Regarding current trading prices, SOLV is priced at $78.01 on the NYSE, while BKDT trades at $77.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.50, whereas BKDT's P/E ratio is N/A. In terms of profitability, SOLV's ROE is +0.31%, compared to BKDT's ROE of +401.19%. Regarding short-term risk, SOLV is more volatile compared to BKDT. This indicates higher risk in terms of short-term price fluctuations for SOLV.Check BKDT's competition here
U.S. Physical Therapy, Inc. (NYSE: USPH)
SOLV vs USPH Comparison July 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.5B. In comparison, USPH has a market cap of 1.1B. Regarding current trading prices, SOLV is priced at $78.01 on the NYSE, while USPH trades at $74.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.50, whereas USPH's P/E ratio is 28.74. In terms of profitability, SOLV's ROE is +0.31%, compared to USPH's ROE of +0.00%. Regarding short-term risk, SOLV is less volatile compared to USPH. This indicates lower risk in terms of short-term price fluctuations for SOLV.Check USPH's competition here
COMPASS Pathways plc (NASDAQ: CMPS)
SOLV vs CMPS Comparison July 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.5B. In comparison, CMPS has a market cap of 1.1B. Regarding current trading prices, SOLV is priced at $78.01 on the NYSE, while CMPS trades at $11.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.50, whereas CMPS's P/E ratio is -5.49. In terms of profitability, SOLV's ROE is +0.31%, compared to CMPS's ROE of -1.51%. Regarding short-term risk, SOLV is less volatile compared to CMPS. This indicates lower risk in terms of short-term price fluctuations for SOLV.Check CMPS's competition here
Fidelity Select Health Care Svcs Port (NASDAQ: FSHCX)
SOLV vs FSHCX Comparison July 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.5B. In comparison, FSHCX has a market cap of 882M. Regarding current trading prices, SOLV is priced at $78.01 on the NYSE, while FSHCX trades at $120.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.50, whereas FSHCX's P/E ratio is N/A. In terms of profitability, SOLV's ROE is +0.31%, compared to FSHCX's ROE of N/A. Regarding short-term risk, SOLV is more volatile compared to FSHCX. This indicates higher risk in terms of short-term price fluctuations for SOLV.Check FSHCX's competition here
Talkspace, Inc. (NASDAQ: TALKW)
SOLV vs TALKW Comparison July 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.5B. In comparison, TALKW has a market cap of 874.4M. Regarding current trading prices, SOLV is priced at $78.01 on the NYSE, while TALKW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.50, whereas TALKW's P/E ratio is N/A. In terms of profitability, SOLV's ROE is +0.31%, compared to TALKW's ROE of +0.01%. Regarding short-term risk, SOLV is less volatile compared to TALKW. This indicates lower risk in terms of short-term price fluctuations for SOLV.Check TALKW's competition here
Talkspace, Inc. (NASDAQ: TALK)
SOLV vs TALK Comparison July 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.5B. In comparison, TALK has a market cap of 872.7M. Regarding current trading prices, SOLV is priced at $78.01 on the NYSE, while TALK trades at $5.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.50, whereas TALK's P/E ratio is 768.44. In terms of profitability, SOLV's ROE is +0.31%, compared to TALK's ROE of +0.01%. Regarding short-term risk, SOLV is more volatile compared to TALK. This indicates higher risk in terms of short-term price fluctuations for SOLV.Check TALK's competition here
Nutex Health, Inc. (NASDAQ: NUTX)
SOLV vs NUTX Comparison July 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.5B. In comparison, NUTX has a market cap of 868.6M. Regarding current trading prices, SOLV is priced at $78.01 on the NYSE, while NUTX trades at $145.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.50, whereas NUTX's P/E ratio is 11.27. In terms of profitability, SOLV's ROE is +0.31%, compared to NUTX's ROE of +0.31%. Regarding short-term risk, SOLV is less volatile compared to NUTX. This indicates lower risk in terms of short-term price fluctuations for SOLV.Check NUTX's competition here
Sonida Senior Living, Inc. (NYSE: SNDA)
SOLV vs SNDA Comparison July 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.5B. In comparison, SNDA has a market cap of 833.8M. Regarding current trading prices, SOLV is priced at $78.01 on the NYSE, while SNDA trades at $41.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.50, whereas SNDA's P/E ratio is -7.72. In terms of profitability, SOLV's ROE is +0.31%, compared to SNDA's ROE of -0.35%. Regarding short-term risk, SOLV is less volatile compared to SNDA. This indicates lower risk in terms of short-term price fluctuations for SOLV.Check SNDA's competition here
Enhabit, Inc. (NYSE: EHAB)
SOLV vs EHAB Comparison July 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.5B. In comparison, EHAB has a market cap of 706.9M. Regarding current trading prices, SOLV is priced at $78.01 on the NYSE, while EHAB trades at $13.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.50, whereas EHAB's P/E ratio is -197.14. In terms of profitability, SOLV's ROE is +0.31%, compared to EHAB's ROE of -0.01%. Regarding short-term risk, SOLV is more volatile compared to EHAB. This indicates higher risk in terms of short-term price fluctuations for SOLV.Check EHAB's competition here
GMR Solutions Inc. (NYSE: GMRS)
SOLV vs GMRS Comparison July 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.5B. In comparison, GMRS has a market cap of 594M. Regarding current trading prices, SOLV is priced at $78.01 on the NYSE, while GMRS trades at $12.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.50, whereas GMRS's P/E ratio is 5.76. In terms of profitability, SOLV's ROE is +0.31%, compared to GMRS's ROE of +1.01%. Regarding short-term risk, SOLV is less volatile compared to GMRS. This indicates lower risk in terms of short-term price fluctuations for SOLV.Check GMRS's competition here
The Oncology Institute, Inc. (NASDAQ: TOI)
SOLV vs TOI Comparison July 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.5B. In comparison, TOI has a market cap of 497.9M. Regarding current trading prices, SOLV is priced at $78.01 on the NYSE, while TOI trades at $4.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.50, whereas TOI's P/E ratio is -13.83. In terms of profitability, SOLV's ROE is +0.31%, compared to TOI's ROE of +3.27%. Regarding short-term risk, SOLV is less volatile compared to TOI. This indicates lower risk in terms of short-term price fluctuations for SOLV.Check TOI's competition here
Viemed Healthcare, Inc. (NASDAQ: VMD)
SOLV vs VMD Comparison July 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.5B. In comparison, VMD has a market cap of 451.2M. Regarding current trading prices, SOLV is priced at $78.01 on the NYSE, while VMD trades at $11.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.50, whereas VMD's P/E ratio is 31.81. In terms of profitability, SOLV's ROE is +0.31%, compared to VMD's ROE of +0.11%. Regarding short-term risk, SOLV is more volatile compared to VMD. This indicates higher risk in terms of short-term price fluctuations for SOLV.Check VMD's competition here
Charming Medical Limited Class A Ordinary Shares (NASDAQ: MCTA)
SOLV vs MCTA Comparison July 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.5B. In comparison, MCTA has a market cap of 445.6M. Regarding current trading prices, SOLV is priced at $78.01 on the NYSE, while MCTA trades at $29.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.50, whereas MCTA's P/E ratio is 419.36. In terms of profitability, SOLV's ROE is +0.31%, compared to MCTA's ROE of -2.33%. Regarding short-term risk, SOLV is more volatile compared to MCTA. This indicates higher risk in terms of short-term price fluctuations for SOLV.Check MCTA's competition here
Strata Critical Medical, Inc. (NASDAQ: SRTA)
SOLV vs SRTA Comparison July 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.5B. In comparison, SRTA has a market cap of 436.1M. Regarding current trading prices, SOLV is priced at $78.01 on the NYSE, while SRTA trades at $5.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.50, whereas SRTA's P/E ratio is -35.46. In terms of profitability, SOLV's ROE is +0.31%, compared to SRTA's ROE of +0.18%. Regarding short-term risk, SOLV is less volatile compared to SRTA. This indicates lower risk in terms of short-term price fluctuations for SOLV.Check SRTA's competition here
The Oncology Institute, Inc. (NASDAQ: TOIIW)
SOLV vs TOIIW Comparison July 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.5B. In comparison, TOIIW has a market cap of 388.9M. Regarding current trading prices, SOLV is priced at $78.01 on the NYSE, while TOIIW trades at $0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.50, whereas TOIIW's P/E ratio is -0.18. In terms of profitability, SOLV's ROE is +0.31%, compared to TOIIW's ROE of +3.27%. Regarding short-term risk, SOLV is less volatile compared to TOIIW. This indicates lower risk in terms of short-term price fluctuations for SOLV.Check TOIIW's competition here
Community Health Systems, Inc. (NYSE: CYH)
SOLV vs CYH Comparison July 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.5B. In comparison, CYH has a market cap of 384M. Regarding current trading prices, SOLV is priced at $78.01 on the NYSE, while CYH trades at $2.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.50, whereas CYH's P/E ratio is 3.73. In terms of profitability, SOLV's ROE is +0.31%, compared to CYH's ROE of +0.21%. Regarding short-term risk, SOLV is less volatile compared to CYH. This indicates lower risk in terms of short-term price fluctuations for SOLV.Check CYH's competition here
Auna S.A. (NYSE: AUNA)
SOLV vs AUNA Comparison July 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.5B. In comparison, AUNA has a market cap of 373.8M. Regarding current trading prices, SOLV is priced at $78.01 on the NYSE, while AUNA trades at $5.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.50, whereas AUNA's P/E ratio is 4.55. In terms of profitability, SOLV's ROE is +0.31%, compared to AUNA's ROE of +0.04%. Regarding short-term risk, SOLV is less volatile compared to AUNA. This indicates lower risk in terms of short-term price fluctuations for SOLV.Check AUNA's competition here
AirSculpt Technologies, Inc. (NASDAQ: AIRS)
SOLV vs AIRS Comparison July 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.5B. In comparison, AIRS has a market cap of 325.2M. Regarding current trading prices, SOLV is priced at $78.01 on the NYSE, while AIRS trades at $4.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.50, whereas AIRS's P/E ratio is -153.67. In terms of profitability, SOLV's ROE is +0.31%, compared to AIRS's ROE of -0.12%. Regarding short-term risk, SOLV is less volatile compared to AIRS. This indicates lower risk in terms of short-term price fluctuations for SOLV.Check AIRS's competition here
Capital Senior Living Corporation (NYSE: CSU)
SOLV vs CSU Comparison July 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.5B. In comparison, CSU has a market cap of 223.7M. Regarding current trading prices, SOLV is priced at $78.01 on the NYSE, while CSU trades at $33.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.50, whereas CSU's P/E ratio is 0.67. In terms of profitability, SOLV's ROE is +0.31%, compared to CSU's ROE of -0.51%. Regarding short-term risk, SOLV is less volatile compared to CSU. This indicates lower risk in terms of short-term price fluctuations for SOLV.Check CSU's competition here
The Joint Corp. (NASDAQ: JYNT)
SOLV vs JYNT Comparison July 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.5B. In comparison, JYNT has a market cap of 119M. Regarding current trading prices, SOLV is priced at $78.01 on the NYSE, while JYNT trades at $8.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.50, whereas JYNT's P/E ratio is 83.50. In terms of profitability, SOLV's ROE is +0.31%, compared to JYNT's ROE of +0.17%. Regarding short-term risk, SOLV is less volatile compared to JYNT. This indicates lower risk in terms of short-term price fluctuations for SOLV.Check JYNT's competition here
biote Corp. (NASDAQ: BTMD)
SOLV vs BTMD Comparison July 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.5B. In comparison, BTMD has a market cap of 100.6M. Regarding current trading prices, SOLV is priced at $78.01 on the NYSE, while BTMD trades at $2.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.50, whereas BTMD's P/E ratio is 5.18. In terms of profitability, SOLV's ROE is +0.31%, compared to BTMD's ROE of -0.23%. Regarding short-term risk, SOLV is less volatile compared to BTMD. This indicates lower risk in terms of short-term price fluctuations for SOLV.Check BTMD's competition here
Five Star Senior Living Inc. (NASDAQ: FVE)
SOLV vs FVE Comparison July 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.5B. In comparison, FVE has a market cap of 98.4M. Regarding current trading prices, SOLV is priced at $78.01 on the NYSE, while FVE trades at $2.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.50, whereas FVE's P/E ratio is -5.64. In terms of profitability, SOLV's ROE is +0.31%, compared to FVE's ROE of -0.15%. Regarding short-term risk, SOLV is less volatile compared to FVE. This indicates lower risk in terms of short-term price fluctuations for SOLV.Check FVE's competition here
Kindly MD, Inc. (NASDAQ: KDLYW)
SOLV vs KDLYW Comparison July 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.5B. In comparison, KDLYW has a market cap of 96.5M. Regarding current trading prices, SOLV is priced at $78.01 on the NYSE, while KDLYW trades at $18.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.50, whereas KDLYW's P/E ratio is N/A. In terms of profitability, SOLV's ROE is +0.31%, compared to KDLYW's ROE of -0.85%. Regarding short-term risk, SOLV is less volatile compared to KDLYW. This indicates lower risk in terms of short-term price fluctuations for SOLV.Check KDLYW's competition here
DocGo Inc. (NASDAQ: DCGO)
SOLV vs DCGO Comparison July 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.5B. In comparison, DCGO has a market cap of 58.9M. Regarding current trading prices, SOLV is priced at $78.01 on the NYSE, while DCGO trades at $0.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.50, whereas DCGO's P/E ratio is -0.68. In terms of profitability, SOLV's ROE is +0.31%, compared to DCGO's ROE of -0.89%. Regarding short-term risk, SOLV is less volatile compared to DCGO. This indicates lower risk in terms of short-term price fluctuations for SOLV.Check DCGO's competition here
AlerisLife Inc. (NASDAQ: ALR)
SOLV vs ALR Comparison July 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.5B. In comparison, ALR has a market cap of 44.2M. Regarding current trading prices, SOLV is priced at $78.01 on the NYSE, while ALR trades at $1.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.50, whereas ALR's P/E ratio is -1.11. In terms of profitability, SOLV's ROE is +0.31%, compared to ALR's ROE of -0.15%. Regarding short-term risk, SOLV is more volatile compared to ALR. This indicates higher risk in terms of short-term price fluctuations for SOLV.Check ALR's competition here
Park Dental Partners, Inc. Common Stock (NASDAQ: PARK)
SOLV vs PARK Comparison July 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.5B. In comparison, PARK has a market cap of 36.5M. Regarding current trading prices, SOLV is priced at $78.01 on the NYSE, while PARK trades at $18.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.50, whereas PARK's P/E ratio is 25.36. In terms of profitability, SOLV's ROE is +0.31%, compared to PARK's ROE of -0.24%. Regarding short-term risk, SOLV is less volatile compared to PARK. This indicates lower risk in terms of short-term price fluctuations for SOLV.Check PARK's competition here
IMAC Holdings, Inc. (NASDAQ: IMAC)
SOLV vs IMAC Comparison July 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.5B. In comparison, IMAC has a market cap of 33.1M. Regarding current trading prices, SOLV is priced at $78.01 on the NYSE, while IMAC trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.50, whereas IMAC's P/E ratio is -2.27. In terms of profitability, SOLV's ROE is +0.31%, compared to IMAC's ROE of +0.00%. Regarding short-term risk, SOLV is less volatile compared to IMAC. This indicates lower risk in terms of short-term price fluctuations for SOLV.Check IMAC's competition here
P3 Health Partners Inc. (NASDAQ: PIII)
SOLV vs PIII Comparison July 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.5B. In comparison, PIII has a market cap of 31.5M. Regarding current trading prices, SOLV is priced at $78.01 on the NYSE, while PIII trades at $9.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.50, whereas PIII's P/E ratio is -0.24. In terms of profitability, SOLV's ROE is +0.31%, compared to PIII's ROE of +1.85%. Regarding short-term risk, SOLV is less volatile compared to PIII. This indicates lower risk in terms of short-term price fluctuations for SOLV.Check PIII's competition here
Cryo-Cell International, Inc. (AMEX: CCEL)
SOLV vs CCEL Comparison July 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.5B. In comparison, CCEL has a market cap of 28.1M. Regarding current trading prices, SOLV is priced at $78.01 on the NYSE, while CCEL trades at $3.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.50, whereas CCEL's P/E ratio is -10.55. In terms of profitability, SOLV's ROE is +0.31%, compared to CCEL's ROE of +0.14%. Regarding short-term risk, SOLV is less volatile compared to CCEL. This indicates lower risk in terms of short-term price fluctuations for SOLV.Check CCEL's competition here
Cano Health, Inc. (NYSE: CANO-WT)
SOLV vs CANO-WT Comparison July 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.5B. In comparison, CANO-WT has a market cap of 19.3M. Regarding current trading prices, SOLV is priced at $78.01 on the NYSE, while CANO-WT trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.50, whereas CANO-WT's P/E ratio is N/A. In terms of profitability, SOLV's ROE is +0.31%, compared to CANO-WT's ROE of -1.49%. Regarding short-term risk, SOLV is less volatile compared to CANO-WT. This indicates lower risk in terms of short-term price fluctuations for SOLV.Check CANO-WT's competition here
Aesthetic Medical International Holdings Group Limited (NASDAQ: AIH)
SOLV vs AIH Comparison July 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.5B. In comparison, AIH has a market cap of 15.9M. Regarding current trading prices, SOLV is priced at $78.01 on the NYSE, while AIH trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.50, whereas AIH's P/E ratio is -2.78. In terms of profitability, SOLV's ROE is +0.31%, compared to AIH's ROE of +1.16%. Regarding short-term risk, SOLV is less volatile compared to AIH. This indicates lower risk in terms of short-term price fluctuations for SOLV.Check AIH's competition here
Cano Health, Inc. (NYSE: CANO)
SOLV vs CANO Comparison July 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.5B. In comparison, CANO has a market cap of 12.4M. Regarding current trading prices, SOLV is priced at $78.01 on the NYSE, while CANO trades at $2.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.50, whereas CANO's P/E ratio is -0.01. In terms of profitability, SOLV's ROE is +0.31%, compared to CANO's ROE of -1.49%. Regarding short-term risk, SOLV is less volatile compared to CANO. This indicates lower risk in terms of short-term price fluctuations for SOLV.Check CANO's competition here
Avem Health Partners, Inc. (NYSE: FPCG)
SOLV vs FPCG Comparison July 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.5B. In comparison, FPCG has a market cap of 10.1M. Regarding current trading prices, SOLV is priced at $78.01 on the NYSE, while FPCG trades at $1,025.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.50, whereas FPCG's P/E ratio is 0.09. In terms of profitability, SOLV's ROE is +0.31%, compared to FPCG's ROE of +0.00%. Regarding short-term risk, SOLV is more volatile compared to FPCG. This indicates higher risk in terms of short-term price fluctuations for SOLV.Check FPCG's competition here
Field Trip Health Ltd. (NASDAQ: FTRP)
SOLV vs FTRP Comparison July 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.5B. In comparison, FTRP has a market cap of 9.8M. Regarding current trading prices, SOLV is priced at $78.01 on the NYSE, while FTRP trades at $0.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.50, whereas FTRP's P/E ratio is -1.22. In terms of profitability, SOLV's ROE is +0.31%, compared to FTRP's ROE of -0.62%. Regarding short-term risk, SOLV is less volatile compared to FTRP. This indicates lower risk in terms of short-term price fluctuations for SOLV.Check FTRP's competition here
American Shared Hospital Services (AMEX: AMS)
SOLV vs AMS Comparison July 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.5B. In comparison, AMS has a market cap of 9.5M. Regarding current trading prices, SOLV is priced at $78.01 on the NYSE, while AMS trades at $1.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.50, whereas AMS's P/E ratio is -6.47. In terms of profitability, SOLV's ROE is +0.31%, compared to AMS's ROE of -0.06%. Regarding short-term risk, SOLV is less volatile compared to AMS. This indicates lower risk in terms of short-term price fluctuations for SOLV.Check AMS's competition here
Basel Medical Group Ltd Ordinary Shares (NASDAQ: BMGL)
SOLV vs BMGL Comparison July 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.5B. In comparison, BMGL has a market cap of 9.2M. Regarding current trading prices, SOLV is priced at $78.01 on the NYSE, while BMGL trades at $5.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.50, whereas BMGL's P/E ratio is -1.11. In terms of profitability, SOLV's ROE is +0.31%, compared to BMGL's ROE of -1.74%. Regarding short-term risk, SOLV is less volatile compared to BMGL. This indicates lower risk in terms of short-term price fluctuations for SOLV.Check BMGL's competition here
XWELL, Inc. (NASDAQ: XWEL)
SOLV vs XWEL Comparison July 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.5B. In comparison, XWEL has a market cap of 6.4M. Regarding current trading prices, SOLV is priced at $78.01 on the NYSE, while XWEL trades at $1.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.50, whereas XWEL's P/E ratio is -0.32. In terms of profitability, SOLV's ROE is +0.31%, compared to XWEL's ROE of +2.89%. Regarding short-term risk, SOLV is less volatile compared to XWEL. This indicates lower risk in terms of short-term price fluctuations for SOLV.Check XWEL's competition here
ModivCare Inc. (NASDAQ: MODV)
SOLV vs MODV Comparison July 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.5B. In comparison, MODV has a market cap of 6.2M. Regarding current trading prices, SOLV is priced at $78.01 on the NYSE, while MODV trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.50, whereas MODV's P/E ratio is -0.06. In terms of profitability, SOLV's ROE is +0.31%, compared to MODV's ROE of +1.36%. Regarding short-term risk, SOLV is more volatile compared to MODV. This indicates higher risk in terms of short-term price fluctuations for SOLV.Check MODV's competition here
Greenbrook TMS Inc. (NASDAQ: GBNH)
SOLV vs GBNH Comparison July 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.5B. In comparison, GBNH has a market cap of 5.5M. Regarding current trading prices, SOLV is priced at $78.01 on the NYSE, while GBNH trades at $0.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.50, whereas GBNH's P/E ratio is -0.06. In terms of profitability, SOLV's ROE is +0.31%, compared to GBNH's ROE of +15.74%. Regarding short-term risk, SOLV is less volatile compared to GBNH. This indicates lower risk in terms of short-term price fluctuations for SOLV.Check GBNH's competition here
Regional Health Properties, Inc. (AMEX: RHE-PA)
SOLV vs RHE-PA Comparison July 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.5B. In comparison, RHE-PA has a market cap of 5.2M. Regarding current trading prices, SOLV is priced at $78.01 on the NYSE, while RHE-PA trades at $0.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.50, whereas RHE-PA's P/E ratio is -0.09. In terms of profitability, SOLV's ROE is +0.31%, compared to RHE-PA's ROE of +2.11%. Regarding short-term risk, SOLV is less volatile compared to RHE-PA. This indicates lower risk in terms of short-term price fluctuations for SOLV.Check RHE-PA's competition here
Regional Health Properties, Inc. (AMEX: RHE)
SOLV vs RHE Comparison July 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.5B. In comparison, RHE has a market cap of 5.2M. Regarding current trading prices, SOLV is priced at $78.01 on the NYSE, while RHE trades at $2.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.50, whereas RHE's P/E ratio is -1.79. In terms of profitability, SOLV's ROE is +0.31%, compared to RHE's ROE of -0.36%. Regarding short-term risk, SOLV is less volatile compared to RHE. This indicates lower risk in terms of short-term price fluctuations for SOLV.Check RHE's competition here
20/20 Biolabs Inc. (NASDAQ: AIDX)
SOLV vs AIDX Comparison July 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.5B. In comparison, AIDX has a market cap of 2.8M. Regarding current trading prices, SOLV is priced at $78.01 on the NYSE, while AIDX trades at $0.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.50, whereas AIDX's P/E ratio is -0.93. In terms of profitability, SOLV's ROE is +0.31%, compared to AIDX's ROE of +0.79%. Regarding short-term risk, SOLV is less volatile compared to AIDX. This indicates lower risk in terms of short-term price fluctuations for SOLV.Check AIDX's competition here
IMAC Holdings, Inc. (NASDAQ: IMACW)
SOLV vs IMACW Comparison July 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.5B. In comparison, IMACW has a market cap of 1.7M. Regarding current trading prices, SOLV is priced at $78.01 on the NYSE, while IMACW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.50, whereas IMACW's P/E ratio is N/A. In terms of profitability, SOLV's ROE is +0.31%, compared to IMACW's ROE of +0.73%. Regarding short-term risk, SOLV is less volatile compared to IMACW. This indicates lower risk in terms of short-term price fluctuations for SOLV.Check IMACW's competition here
Nakamoto Inc. (NASDAQ: NAKAW)
SOLV vs NAKAW Comparison July 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.5B. In comparison, NAKAW has a market cap of 1.5M. Regarding current trading prices, SOLV is priced at $78.01 on the NYSE, while NAKAW trades at $0.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.50, whereas NAKAW's P/E ratio is -0.53. In terms of profitability, SOLV's ROE is +0.31%, compared to NAKAW's ROE of -0.85%. Regarding short-term risk, SOLV is more volatile compared to NAKAW. This indicates higher risk in terms of short-term price fluctuations for SOLV.Check NAKAW's competition here
Concord Medical Services Holdings Limited (NYSE: CCM)
SOLV vs CCM Comparison July 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.5B. In comparison, CCM has a market cap of 626.1K. Regarding current trading prices, SOLV is priced at $78.01 on the NYSE, while CCM trades at $4.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.50, whereas CCM's P/E ratio is -0.29. In terms of profitability, SOLV's ROE is +0.31%, compared to CCM's ROE of +0.06%. Regarding short-term risk, SOLV is less volatile compared to CCM. This indicates lower risk in terms of short-term price fluctuations for SOLV.Check CCM's competition here
NewGenIvf Group Limited (NASDAQ: NIVF)
SOLV vs NIVF Comparison July 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.5B. In comparison, NIVF has a market cap of 212.3K. Regarding current trading prices, SOLV is priced at $78.01 on the NYSE, while NIVF trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.50, whereas NIVF's P/E ratio is 0.55. In terms of profitability, SOLV's ROE is +0.31%, compared to NIVF's ROE of +0.33%. Regarding short-term risk, SOLV is less volatile compared to NIVF. This indicates lower risk in terms of short-term price fluctuations for SOLV.Check NIVF's competition here
Mobile-health Network Solutions Class A Ordinary Shares (NASDAQ: MNDR)
SOLV vs MNDR Comparison July 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.5B. In comparison, MNDR has a market cap of 53.6K. Regarding current trading prices, SOLV is priced at $78.01 on the NYSE, while MNDR trades at $2.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.50, whereas MNDR's P/E ratio is -0.05. In terms of profitability, SOLV's ROE is +0.31%, compared to MNDR's ROE of -0.46%. Regarding short-term risk, SOLV is less volatile compared to MNDR. This indicates lower risk in terms of short-term price fluctuations for SOLV.Check MNDR's competition here
NewGenIvf Group Limited (NASDAQ: NIVFW)
SOLV vs NIVFW Comparison July 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.5B. In comparison, NIVFW has a market cap of 50K. Regarding current trading prices, SOLV is priced at $78.01 on the NYSE, while NIVFW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.50, whereas NIVFW's P/E ratio is -0.01. In terms of profitability, SOLV's ROE is +0.31%, compared to NIVFW's ROE of +0.33%. Regarding short-term risk, SOLV is less volatile compared to NIVFW. This indicates lower risk in terms of short-term price fluctuations for SOLV.Check NIVFW's competition here
DocGo Inc. (NASDAQ: DCGOW)
SOLV vs DCGOW Comparison July 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.5B. In comparison, DCGOW has a market cap of 0. Regarding current trading prices, SOLV is priced at $78.01 on the NYSE, while DCGOW trades at $1.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.50, whereas DCGOW's P/E ratio is N/A. In terms of profitability, SOLV's ROE is +0.31%, compared to DCGOW's ROE of -0.89%. Regarding short-term risk, SOLV is less volatile compared to DCGOW. This indicates lower risk in terms of short-term price fluctuations for SOLV.Check DCGOW's competition here
SOC Telemed, Inc. (NASDAQ: TLMDW)
SOLV vs TLMDW Comparison July 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.5B. In comparison, TLMDW has a market cap of 0. Regarding current trading prices, SOLV is priced at $78.01 on the NYSE, while TLMDW trades at $0.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.50, whereas TLMDW's P/E ratio is N/A. In terms of profitability, SOLV's ROE is +0.31%, compared to TLMDW's ROE of -0.46%. Regarding short-term risk, SOLV is less volatile compared to TLMDW. This indicates lower risk in terms of short-term price fluctuations for SOLV.Check TLMDW's competition here
Hanger, Inc. (NYSE: HNGR)
SOLV vs HNGR Comparison July 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.5B. In comparison, HNGR has a market cap of 0. Regarding current trading prices, SOLV is priced at $78.01 on the NYSE, while HNGR trades at $18.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.50, whereas HNGR's P/E ratio is 19.71. In terms of profitability, SOLV's ROE is +0.31%, compared to HNGR's ROE of +0.52%. Regarding short-term risk, SOLV is more volatile compared to HNGR. This indicates higher risk in terms of short-term price fluctuations for SOLV.Check HNGR's competition here
ATI Physical Therapy, Inc. (NYSE: ATIP-WT)
SOLV vs ATIP-WT Comparison July 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.5B. In comparison, ATIP-WT has a market cap of 0. Regarding current trading prices, SOLV is priced at $78.01 on the NYSE, while ATIP-WT trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.50, whereas ATIP-WT's P/E ratio is N/A. In terms of profitability, SOLV's ROE is +0.31%, compared to ATIP-WT's ROE of +2.05%. Regarding short-term risk, SOLV is less volatile compared to ATIP-WT. This indicates lower risk in terms of short-term price fluctuations for SOLV.Check ATIP-WT's competition here
Tivity Health, Inc. (NASDAQ: TVTY)
SOLV vs TVTY Comparison July 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.5B. In comparison, TVTY has a market cap of 0. Regarding current trading prices, SOLV is priced at $78.01 on the NYSE, while TVTY trades at $32.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.50, whereas TVTY's P/E ratio is 19.06. In terms of profitability, SOLV's ROE is +0.31%, compared to TVTY's ROE of +1.75%. Regarding short-term risk, SOLV is more volatile compared to TVTY. This indicates higher risk in terms of short-term price fluctuations for SOLV.Check TVTY's competition here
New Frontier Health Corporation (NYSE: NFH)
SOLV vs NFH Comparison July 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.5B. In comparison, NFH has a market cap of 0. Regarding current trading prices, SOLV is priced at $78.01 on the NYSE, while NFH trades at $11.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.50, whereas NFH's P/E ratio is -19.75. In terms of profitability, SOLV's ROE is +0.31%, compared to NFH's ROE of -0.06%. Regarding short-term risk, SOLV is more volatile compared to NFH. This indicates higher risk in terms of short-term price fluctuations for SOLV.Check NFH's competition here
Skylight Health Group Inc. (NASDAQ: SLHGP)
SOLV vs SLHGP Comparison July 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.5B. In comparison, SLHGP has a market cap of 0. Regarding current trading prices, SOLV is priced at $78.01 on the NYSE, while SLHGP trades at $12.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.50, whereas SLHGP's P/E ratio is -30.38. In terms of profitability, SOLV's ROE is +0.31%, compared to SLHGP's ROE of -0.48%. Regarding short-term risk, SOLV is more volatile compared to SLHGP. This indicates higher risk in terms of short-term price fluctuations for SOLV.Check SLHGP's competition here
Skylight Health Group Inc. (NASDAQ: SLHG)
SOLV vs SLHG Comparison July 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.5B. In comparison, SLHG has a market cap of 0. Regarding current trading prices, SOLV is priced at $78.01 on the NYSE, while SLHG trades at $0.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.50, whereas SLHG's P/E ratio is -1.48. In terms of profitability, SOLV's ROE is +0.31%, compared to SLHG's ROE of N/A. Regarding short-term risk, SOLV is less volatile compared to SLHG. This indicates lower risk in terms of short-term price fluctuations for SOLV.Check SLHG's competition here
Diversicare Healthcare Services, Inc. (NASDAQ: DVCR)
SOLV vs DVCR Comparison July 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.5B. In comparison, DVCR has a market cap of 0. Regarding current trading prices, SOLV is priced at $78.01 on the NYSE, while DVCR trades at $10.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.50, whereas DVCR's P/E ratio is 28.34. In terms of profitability, SOLV's ROE is +0.31%, compared to DVCR's ROE of -0.15%. Regarding short-term risk, SOLV is more volatile compared to DVCR. This indicates higher risk in terms of short-term price fluctuations for SOLV.Check DVCR's competition here
Almost Family Inc. (NASDAQ: AFAM)
SOLV vs AFAM Comparison July 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.5B. In comparison, AFAM has a market cap of 0. Regarding current trading prices, SOLV is priced at $78.01 on the NYSE, while AFAM trades at $56.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.50, whereas AFAM's P/E ratio is N/A. In terms of profitability, SOLV's ROE is +0.31%, compared to AFAM's ROE of +0.06%. Regarding short-term risk, SOLV is less volatile compared to AFAM. This indicates lower risk in terms of short-term price fluctuations for SOLV.Check AFAM's competition here
SOC Telemed, Inc. (NASDAQ: TLMD)
SOLV vs TLMD Comparison July 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.5B. In comparison, TLMD has a market cap of 0. Regarding current trading prices, SOLV is priced at $78.01 on the NYSE, while TLMD trades at $3.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.50, whereas TLMD's P/E ratio is -1.60. In terms of profitability, SOLV's ROE is +0.31%, compared to TLMD's ROE of -0.46%. Regarding short-term risk, SOLV is more volatile compared to TLMD. This indicates higher risk in terms of short-term price fluctuations for SOLV.Check TLMD's competition here
Kindred Healthcare, Inc. (NYSE: KND)
SOLV vs KND Comparison July 2026
Solventum Corporation (NYSE: SOLV) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SOLV stands at 13.5B. In comparison, KND has a market cap of 0. Regarding current trading prices, SOLV is priced at $78.01 on the NYSE, while KND trades at $9.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SOLV currently has a P/E ratio of 12.50, whereas KND's P/E ratio is -1.14. In terms of profitability, SOLV's ROE is +0.31%, compared to KND's ROE of -0.53%. Regarding short-term risk, SOLV is more volatile compared to KND. This indicates higher risk in terms of short-term price fluctuations for SOLV.Check KND's competition here